Non steroidal anti-inflammatory drugs;Anti-inflammatoires non stéroïdiens

Revue du Praticien

Volumn 53, Issue 5, 2003, Pages 502-506

  Berenbaum, Francis ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL PRACTICE; DRUG EFFICACY; DRUG TOLERABILITY; FEVER; HUMAN; INFLAMMATION; PAIN; PRESCRIPTION; REVIEW; STOMACH ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; ENZYME INHIBITORS; FEVER; HUMANS; INFLAMMATION; ISOENZYMES; MEMBRANE PROTEINS; PAIN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; STOMACH ULCER; THROMBOSIS;

EID: 0037344074     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Berenbaum F. Cyclo-oxygenases and cyclo-oxygenase inhibitors: is a new class of drugs in the making? Rev Rhum Engl Ed 1998; 65: 634-40.
2. Berenbaum F. Prescription et surveillance des anti-inflammatoires stéroïdiens et non stéroïdiens. Rev Prat (à paraître).
3. Schumacher HR Jr, Boice JA, Daikh DI et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002; 324: 1488-92.
4. Amor B, Dougados M, Khan MA. Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am 1995; 21: 117-28.
5. Dougados M, Behier JM, Jolchine I et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001; 44: 180-5.
6. Pendleton A, Arden N, Dougados M et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000; 59: 936-44.
7. American College of Rheumatology subcommittee on osteoarthritis guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43: 1905-15.
8. Pincus T, Koch GG, Sokka T et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001; 44: 1587-98.
9. Brandt KD. Simple analgesics versus NSAID. J Rheumatol 2002; 29: 640-2.
10. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the anti-platelet effects of aspirin. N Engl J Med 2001; 345: 1809-17.
11. Voutilainen M, Mantynen T, Farkkila M, Juhola M, Sipponen P. Impact of non-steroidal anti-inflammatory drug and aspirin use on the prevalence of dyspepsia and uncomplicated peptic ulcer disease. Scand J Gastroenterol 2001; 36: 817-21.
12. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987; 82: 1153-8.
13. Chan FK, To KF, Wu JC et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359: 9-13.
14. Hawkey CJ, Tulassay Z, Szczepanski L et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter eradication for lesion prevention. Lancet 1998; 352: 1016-21.
15. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55.
16. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8.
17. Mizuno H, Sakamoto C, Matsuda K et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112: 387-97.
18. Harris CJ, Brater DC. Renal effects of cyclooxygenase-2 selective inhibitors. Curr Opin Nephrol Hypertens 2001; 10: 603-10.
19. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8: 85-95.
20. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999; 96: 272-7.
21. Konstam MA,Weir MR, Reicin A et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104: 2280-8.
22. Ribard P, Gaudouen C, Gaudouen Y, Dryll A. Accidents cutanés des anti-inflammatoires non stéroïdiens. In: De Sèze, Ryckewaert A, Kahn MF, Kuntz D, Dryll A, Guérin C (eds). Actualités rhumatologiques présentées au praticien. Paris: Expansion Scientifique Française, 1987: 326-35.
23. Dahlen B, Szczeklik A, Murray JJ. Celecoxib in patients with asthma and aspirin intolerance.The Celecoxib in Aspirin-Intolerant Asthma Study Group. N Engl J Med 2001; 344: 142.